Leuprolide TFA
Modify Date: 2024-01-02 12:29:33
Leuprolide TFA structure
|
Common Name | Leuprolide TFA | ||
|---|---|---|---|---|
| CAS Number | 53714-56-0 | Molecular Weight | 1209.40 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C59H84N16O12 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
| Symbol |
GHS08 |
Signal Word | Danger | |
Use of Leuprolide TFALeuprolide is an agonist at pituitary GnRH receptors. Target: GnRH receptorLeuprorelin is a gonadotrophin-releasing hormone (GnRH) analogue used to treat a wide range of sex hormone-related disorders including advanced prostatic cancer, endometriosis and precocious puberty. Leuprorelin acts primarily on the anterior pituitary, inducing a transient early rise in gonadotrophin release. With continued use, Leuprorelin causes pituitary desensitisation and/or down-regulation, leading to suppressed circulating levels of gonadotrophins and sex hormones. [1] By interrupting the normal pulsatile stimulation of, and thus desensitizing, the GnRH receptors, it indirectly downregulates the secretion of gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to hypogonadism and thus a dramatic reduction in estradiol and testosterone levels in both sexes. [2] |
| Name | leuprolide |
|---|---|
| Synonym | More Synonyms |
| Description | Leuprolide is an agonist at pituitary GnRH receptors. Target: GnRH receptorLeuprorelin is a gonadotrophin-releasing hormone (GnRH) analogue used to treat a wide range of sex hormone-related disorders including advanced prostatic cancer, endometriosis and precocious puberty. Leuprorelin acts primarily on the anterior pituitary, inducing a transient early rise in gonadotrophin release. With continued use, Leuprorelin causes pituitary desensitisation and/or down-regulation, leading to suppressed circulating levels of gonadotrophins and sex hormones. [1] By interrupting the normal pulsatile stimulation of, and thus desensitizing, the GnRH receptors, it indirectly downregulates the secretion of gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to hypogonadism and thus a dramatic reduction in estradiol and testosterone levels in both sexes. [2] |
|---|---|
| Related Catalog | |
| References |
[2]. Leuprorelin |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Molecular Formula | C59H84N16O12 |
| Molecular Weight | 1209.40 |
| PSA | 466.34000 |
| LogP | 0.41 |
| Index of Refraction | 1.682 |
| Storage condition | −20°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H360 |
| Precautionary Statements | P201-P280-P308 + P313 |
| Safety Phrases | S22-S24/25 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 2 |
| RTECS | OH6390000 |
|
~%
Leuprolide TFA CAS#:53714-56-0 |
| Literature: US2006/276626 A1, ; Page/Page column 13 ; |
|
Estradiol, but not testosterone, heightens cortisol-mediated negative feedback on pulsatile ACTH secretion and ACTH approximate entropy in unstressed older men and women.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 306(9) , R627-35, (2014) How sex steroids modulate glucocorticoid feedback on the hypothalamic-pituitary-corticotrope (HPC) unit is controversial in humans. We postulated that testosterone (T) in men and estradiol (E2) in wom... |
|
|
Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients.
Med. Oncol. 30(1) , 354, (2013) Data comparing the efficacy of monthly and trimonthly formulations of LHRH agonists are lacking. The aim of this study was to compare the effects of monthly goserelin and trimonthly leuprolide on estr... |
|
|
Novasure as a mechanical endometrial preparation agent in large uteri.
JSLS 16(4) , 537-41, (2012) We evaluated Novasure ablation as a mechanical endometrial preparation agent before Roller Ball endometrial ablation in lieu of GnRH agonists in large uteri.A retrospective chart review of 20 consecut... |
| Enantone |
| Leuprorelin |
| L-Prolinamide, 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl- |
| Leuplin |
| Leuprolide |
| nghormone |
| des-Gly10 ethylamide]gonadotropin releasing hormone |
| MFCD00167544 |
| LH-RH LEUPROLIDE |
| Carcinil |
| 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide |
| pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHC2H5 |
| Lucrin |
| <D-Leu6,DesGly10> LHRH ethylamide |
| LEUPROPELIN |
| Leuprorelin Acetate |
| GLP-HIS-TRP-SER-TYR-DLEU-LEU-ARG-PRO-NHET: GLP-HWSY-DL-LRP-NHET |